Subcutaneous metastasis from an ovarian carcinoma disappeared following tamoxifen therapy

被引：7

作者：

Flam, F

Skoog, L

Wilking, N

机构：

[1] KAROLINSKA HOSP,DEPT CYTOL,S-17176 STOCKHOLM,SWEDEN

[2] KAROLINSKA HOSP,DEPT ONCOL,S-17176 STOCKHOLM,SWEDEN

来源：

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 1996年 / 64卷 / 02期

关键词：

ovarian carcinoma; metastasis; tamoxifen;

D O I：

10.1016/0301-2115(95)02281-3

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In a 78-year-old woman who had been treated for a breast cancer, a subcutaneous metastasis was diagnosed. This metastasis disappeared following a 3-months' treatment with tamoxifen. Only then was the primary tumour found to be ovarian carcinoma rather than a mammary one. This and other reports indicate that hormonal agents may also be considered as a third line of treatment in ovarian carcinoma.

引用

页码：225 / 226

页数：2

共 14 条

[1]

[Anonymous], P 2 EUR C CLIN ONC

[2]

[Anonymous], P AM SOC CLIN ONCOL

[3]

HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO

[4]

2-O

[5] GROWTH-INHIBITION OF ESTROGEN RECEPTOR-POSITIVE HUMAN OVARIAN-CARCINOMA BY ANTIESTROGENS IN-VITRO AND IN A XENOGRAFT MODEL [J].

LANGDON, SP ;

CREW, AJ ;

RITCHIE, AA ;

MUIR, M ;

WAKELING, A ;

SMYTH, JF ;

MILLER, WR .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :682-686

[6] TAMOXIFEN DELAYS THE DEVELOPMENT OF RESISTANCE TO CISPLATIN IN HUMAN-MELANOMA AND OVARIAN-CANCER CELL-LINES [J].

MCCLAY, EF ;

ALBRIGHT, KD ;

JONES, JA ;

CHRISTEN, RD ;

HOWELL, SB .

BRITISH JOURNAL OF CANCER, 1994, 70 (03) :449-452

[7] TAMOXIFEN IN REFRACTORY OVARIAN-CANCER - THE USE OF A LOADING DOSE SCHEDULE [J].

OSBORNE, RJ ;

MALIK, ST ;

SLEVIN, ML ;

HARVEY, VJ ;

SPONA, J ;

SALZER, H ;

WILLIAMS, CJ .

BRITISH JOURNAL OF CANCER, 1988, 57 (01) :115-116

[8]

SCHWARTZ PE, 1982, OBSTET GYNECOL, V59, P583

[9]

SCHWARTZ PE, 1985, OBSTET GYNECOL, V66, P428

[10]

SCHWARTZ PE, 1978, STEROID RECEPTOR PRO

← 1 2 →